Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

EGFR-homing dsRNA activates cancer-targeted immune response and eliminates disseminated EGFR-overexpressing tumors in mice.

Shir A, Ogris M, Roedl W, Wagner E, Levitzki A.

Clin Cancer Res. 2011 Mar 1;17(5):1033-43. doi: 10.1158/1078-0432.CCR-10-1140. Epub 2010 Dec 30.

2.

PolyIC GE11 polyplex inhibits EGFR-overexpressing tumors.

Abourbeh G, Shir A, Mishani E, Ogris M, Rödl W, Wagner E, Levitzki A.

IUBMB Life. 2012 Apr;64(4):324-30. doi: 10.1002/iub.1002. Epub 2012 Feb 23.

3.

EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice.

Shir A, Ogris M, Wagner E, Levitzki A.

PLoS Med. 2006 Jan;3(1):e6. Epub 2005 Dec 6. Erratum in: PLoS Med. 2007 Aug;4(8):e266.

4.

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, Gilmer TM.

Mol Cancer Ther. 2001 Dec;1(2):85-94.

5.

Poly(I:C)-mediated tumor growth suppression in EGF-receptor overexpressing tumors using EGF-polyethylene glycol-linear polyethylenimine as carrier.

Schaffert D, Kiss M, Rödl W, Shir A, Levitzki A, Ogris M, Wagner E.

Pharm Res. 2011 Apr;28(4):731-41. doi: 10.1007/s11095-010-0225-4. Epub 2010 Aug 6.

PMID:
20694527
6.

Disconnecting the yin and yang relation of epidermal growth factor receptor (EGFR)-mediated delivery: a fully synthetic, EGFR-targeted gene transfer system avoiding receptor activation.

Schäfer A, Pahnke A, Schaffert D, van Weerden WM, de Ridder CM, Rödl W, Vetter A, Spitzweg C, Kraaij R, Wagner E, Ogris M.

Hum Gene Ther. 2011 Dec;22(12):1463-73. doi: 10.1089/hum.2010.231. Epub 2011 Aug 10.

7.

Targeting the Immune System to Fight Cancer Using Chemical Receptor Homing Vectors Carrying Polyinosine/Cytosine (PolyIC).

Levitzki A.

Front Oncol. 2012 Feb 8;2:4. doi: 10.3389/fonc.2012.00004. eCollection 2012.

8.

Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice.

Wu W, O'Reilly MS, Langley RR, Tsan RZ, Baker CH, Bekele N, Tang XM, Onn A, Fidler IJ, Herbst RS.

Mol Cancer Ther. 2007 Oct;6(10):2652-63. Epub 2007 Oct 3.

9.

In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor.

Uckun FM, Narla RK, Zeren T, Yanishevski Y, Myers DE, Waurzyniak B, Ek O, Schneider E, Messinger Y, Chelstrom LM, Gunther R, Evans W.

Clin Cancer Res. 1998 May;4(5):1125-34.

10.
11.

Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells.

Amin DN, Bielenberg DR, Lifshits E, Heymach JV, Klagsbrun M.

Microvasc Res. 2008 May;76(1):15-22. doi: 10.1016/j.mvr.2008.01.002. Epub 2008 Mar 18.

PMID:
18440031
13.

Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.

Wang W, Li Q, Yamada T, Matsumoto K, Matsumoto I, Oda M, Watanabe G, Kayano Y, Nishioka Y, Sone S, Yano S.

Clin Cancer Res. 2009 Nov 1;15(21):6630-8. doi: 10.1158/1078-0432.CCR-09-1001. Epub 2009 Oct 20.

14.
15.

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.

Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.

Cancer Res. 2004 Jul 15;64(14):4931-41.

16.

Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer.

Milane L, Duan Z, Amiji M.

PLoS One. 2011;6(9):e24075. doi: 10.1371/journal.pone.0024075. Epub 2011 Sep 8.

17.

Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647.

Gendreau SB, Ventura R, Keast P, Laird AD, Yakes FM, Zhang W, Bentzien F, Cancilla B, Lutman J, Chu F, Jackman L, Shi Y, Yu P, Wang J, Aftab DT, Jaeger CT, Meyer SM, De Costa A, Engell K, Chen J, Martini JF, Joly AH.

Clin Cancer Res. 2007 Jun 15;13(12):3713-23.

18.

Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.

Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S.

Mol Cancer Ther. 2012 Oct;11(10):2149-57. doi: 10.1158/1535-7163.MCT-12-0195. Epub 2012 Jul 25.

19.
20.

Biological evaluation of a novel doxorubicin-peptide conjugate for targeted delivery to EGF receptor-overexpressing tumor cells.

Ai S, Duan J, Liu X, Bock S, Tian Y, Huang Z.

Mol Pharm. 2011 Apr 4;8(2):375-86. doi: 10.1021/mp100243j. Epub 2011 Feb 2.

PMID:
21241067
Items per page

Supplemental Content

Write to the Help Desk